(CAD)
Q3 2025
% Change vs.Q3 2024
YTD 2025
% Change vs.YTD 2024
Trailing Twelve Months (TTM) Sept 30, 2025
% Change vs.TTM Sept 30, 2024
Canadian Pharma Sales
9,864,254
+19%
28,351,130
+16%
36,897,581
+14%
International Pharma Sales
1,153,742
+94%
3,134,572
+316%
3,311,306
+310%
Legacy Business Sales
1,203,808
+83%
1,894,358
+73%
1,967,857
+48%
Total Company Sales
12,221,804
+28%
33,380,060
+27%
42,176,744
+22%
EBITDA¹
3,632,399
+27%
9,594,195
+35%
11,835,307
+35%
Net Income After Taxes (NIAT)
2,682,340
+16%
7,020,444
+24%
8,633,638
+21%
Fully Diluted EPS
0.23
+19%
0.61
+28%
0.75
+25%
Return on Average Equity for TTM September 30, 2025 was 22% as compared to 20% for TTM September 30, 2024
During YTD 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)
Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025, and September 15, 2025
Declared subsequent cash dividend of $0.05 per common share to be paid on December 15, 2025
"BioSyent delivered strong third quarter financial results," commented Mr. René Goehrum, President and CEO of BioSyent. "Each of our three businesses performed well during the quarter, with total Company sales increasing by 28% overall. Though we experienced some gross margin compression on changes in sales mix, our overall EBITDA¹ margin in Q3 2025 remained consistent with the comparative period at 30% to sales as operating expenses were maintained in proportion to sales growth. On a year-to-date basis, total Company sales increased by 27% with an EBITDA¹ margin of 29% to sales. Our FeraMAX® and Tibella® / Tibelia® products continue to generate profitable sales growth, both in Canada and internationally. In just over one year since our September 2024 acquisition of the worldwide rights to Tibella® / Tibelia®, this product has generated incremental sales and profit growth in line with our initial expectations. As we enter the final weeks of the year, we remain focused on continued profitable growth and momentum in our businesses through the end of 2025 and into 2026."
The CEO's presentation on the Q3 and YTD 2025 Results is available at the following link: www.biosyent.com/investors/
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024 will be posted on www.sedarplus.ca on ...
